Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) FCF Margin (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of FCF Margin data on record, last reported at 90.16% in Q4 2025.

  • For Q4 2025, FCF Margin fell 58935.0% year-over-year to 90.16%; the TTM value through Dec 2025 reached 49.55%, up 75608.0%, while the annual FY2025 figure was 49.55%, 75608.0% up from the prior year.
  • FCF Margin reached 90.16% in Q4 2025 per VRCA's latest filing, down from 67.37% in the prior quarter.
  • Across five years, FCF Margin topped out at 499.19% in Q4 2024 and bottomed at 12435.14% in Q1 2023.
  • Average FCF Margin over 5 years is 1787.78%, with a median of 481.41% recorded in 2024.
  • Peak YoY movement for FCF Margin: plummeted -1049894bps in 2023, then soared 1191378bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 92.47% in 2021, then tumbled by -7884bps to 7382.35% in 2022, then skyrocketed by 90bps to 741.15% in 2023, then surged by 167bps to 499.19% in 2024, then tumbled by -118bps to 90.16% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 90.16% in Q4 2025, 67.37% in Q3 2025, and 78.73% in Q2 2025.